Hogan Lovells advises Fresenius Kabi on divestment of Halden plant in Norway

Earlier this year, Fresenius Kabi announced its intention to sell the plant in Halden. This follows the company's Vision 2026 strategy, a comprehensive and global framework for sustainable growth as well as cost and efficiency improvements. 

In the next coming months, the Prange Group, together with its affiliate Adragos Pharma, will take over the Halden plant including equipment and staff, and will continue operations as a contract manufacturing organization for Fresenius Kabi and external customers. Fresenius Kabi’s Norwegian marketing unit will not be affected by the divestment.  

Hogan Lovells has advised Fresenius Kabi on all legal issues in relation to the divestment.

Hogan Lovells Team for Fresenius Kabi AG

Dr Torsten Rosenboom (Partner, Lead), Dr Christoph Naumann (Partner), Andreas Thun (Counsel), Dr Marius Rothermund (Senior Associate), Dr Matthias Murr (Senior Associate), Dr Mike Karl Schmidt (Associate), Hannah Wohlfarth (Associate), Nicolas Persch (Senior Business Lawyer), Melisa Gürsoy (Business Lawyer) (Corporate/ M&A);

Bianca Engelmann (Partner, Finance); 

Arne Thiermann (Partner), Dr Benjamin Goehl (Senior Associate), Marcus Kaiser (Senior Associate), Caroline Schmalenbach (Associate) (Life Sciences);

Dr Marc Schweda (Partner), Dr Jan-Christoph Rudowicz (Counsel) (Antitrust);

Dr Sabrina Gäbeler (Counsel, Employment).

Fresenius Inhouse

Lukas Fleck (Lead), Dr. Jan Winzen